Turn Bio has bolstered its regenerative portfolio by acquiring Harvard's ARMMs platform. CEO Anja Krammer illustrates how merging eTurna and ARMMs allows precise delivery of epigenetic therapies, as seen in promising preclinical data for skin rejuvenation and other age-related treatments.
Q&A
- What is ARMMs technology?
- How does eTurna improve therapy delivery?
- What clinical implications might this acquisition have?